JP5840609B2 - イメージングに用いるパーフルオロ化合物 - Google Patents
イメージングに用いるパーフルオロ化合物 Download PDFInfo
- Publication number
- JP5840609B2 JP5840609B2 JP2012522296A JP2012522296A JP5840609B2 JP 5840609 B2 JP5840609 B2 JP 5840609B2 JP 2012522296 A JP2012522296 A JP 2012522296A JP 2012522296 A JP2012522296 A JP 2012522296A JP 5840609 B2 JP5840609 B2 JP 5840609B2
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- fmri
- imaging
- combination
- perfluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003384 imaging method Methods 0.000 title claims description 45
- -1 Perfluoro compounds Chemical class 0.000 title description 13
- 239000002872 contrast media Substances 0.000 claims description 43
- VLTXBOGHSBHSAC-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]cyclohexane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F VLTXBOGHSBHSAC-UHFFFAOYSA-N 0.000 claims description 27
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 11
- 230000005298 paramagnetic effect Effects 0.000 claims description 9
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 238000002059 diagnostic imaging Methods 0.000 claims description 4
- 238000000163 radioactive labelling Methods 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000000439 tumor marker Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 229960001217 perflubron Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002603 single-photon emission computed tomography Methods 0.000 description 8
- 229910052688 Gadolinium Inorganic materials 0.000 description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical class OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims (6)
- 19FMRIを含む診断用イメージング方法で使用するための造影剤の組み合わせであって、
第1の 19 FMRI造影剤としてのパーフルオロ−t−ブチルシクロヘキサンと、
第2の19FMRI造影剤としてのパーフルオロオクチルブロミドと、
を含み、
当該造影剤の組み合わせは、コアと該コアを囲むリン脂質の乳化剤のシェルとを有するナノ粒子の水性エマルジョンとして使用され、
前記コアは、前記第1の 19 FMRI造影剤および前記第2の 19 FMRI造影剤を有し、
前記シェルは、標的結合のためのリガンド、1HMRI造影剤、放射性ラベル化剤およびそれらの混合物を含む群から選択される、少なくとも1つのイメージング機能を含む、造影剤の組み合わせ。 - 人又は動物で行われる診断用イメージング方法で使用される、請求項1に記載の造影剤の組み合わせ。
- 前記シェルは、標的結合のためのリガンドを含む、請求項1または2に記載の造影剤の組み合わせ。
- 前記シェルは、さらに、常磁性試剤を含む、請求項1乃至3のいずれか一つに記載の造影剤の組み合わせ。
- 当該造影剤の組み合わせは、静脈又は胃腸管投与される、請求項1乃至4のいずれか一つに記載の造影剤の組み合わせ。
- 前記第1の 19 FMRI造影剤は、第1の腫瘍マーカーである第1の標的のための1以上のリガンドを有し、
前記第2の19FMRI造影剤は、前記第1の腫瘍マーカーとは異なる第2の腫瘍マーカーである第2の標的のための1以上のリガンドを有する、請求項1乃至5のいずれか一つに記載の造影剤の組み合わせ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09166955.6 | 2009-07-31 | ||
EP09166955 | 2009-07-31 | ||
PCT/IB2010/053321 WO2011013038A2 (en) | 2009-07-31 | 2010-07-21 | Perfluoro compounds for use in imaging |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015221770A Division JP2016029098A (ja) | 2009-07-31 | 2015-11-12 | イメージングに用いるパーフルオロ化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013500959A JP2013500959A (ja) | 2013-01-10 |
JP2013500959A5 JP2013500959A5 (ja) | 2014-12-18 |
JP5840609B2 true JP5840609B2 (ja) | 2016-01-06 |
Family
ID=43304070
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012522296A Expired - Fee Related JP5840609B2 (ja) | 2009-07-31 | 2010-07-21 | イメージングに用いるパーフルオロ化合物 |
JP2015221770A Pending JP2016029098A (ja) | 2009-07-31 | 2015-11-12 | イメージングに用いるパーフルオロ化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015221770A Pending JP2016029098A (ja) | 2009-07-31 | 2015-11-12 | イメージングに用いるパーフルオロ化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120128589A1 (ja) |
EP (1) | EP2459235B1 (ja) |
JP (2) | JP5840609B2 (ja) |
CN (1) | CN102497888B (ja) |
WO (1) | WO2011013038A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101906574B1 (ko) * | 2013-01-15 | 2018-10-10 | 주식회사 엘지생활건강 | 발수성을 가지는 칫솔모 및 이를 포함하는 칫솔 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4453028A (en) * | 1982-03-29 | 1984-06-05 | Lagow Richard J | Perfluorinated compounds with cyclohexyl groups |
US5236694A (en) | 1990-02-21 | 1993-08-17 | The Board Of Regents, The University Of Texas System | 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents |
US5571498A (en) | 1994-06-02 | 1996-11-05 | Hemagen/Pfc | Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI). |
US6167887B1 (en) * | 1997-11-21 | 2001-01-02 | Synthetic Blood International, Inc. | Selected C-10 perfluorinated hydrocarbons for liquid ventilation and artificial blood |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US6574497B1 (en) * | 2000-12-22 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | MRI medical device markers utilizing fluorine-19 |
US6869591B2 (en) * | 2002-03-26 | 2005-03-22 | Barnes-Jewish Hospital | Paramagnetic particles that provide improved relaxivity |
US8777889B2 (en) * | 2004-06-15 | 2014-07-15 | Ceramatec, Inc. | Apparatus and method for administering a therapeutic agent into tissue |
WO2006046200A1 (en) | 2004-10-29 | 2006-05-04 | Koninklijke Philips Electronics N.V. | Preparation of dispersions of particles for use as contrast agents in ultrasound imaging |
EP2019667A4 (en) * | 2006-04-27 | 2012-08-22 | Barnes Jewish Hospital | DETECTION AND IMAGING OF TARGET TISSUE |
CN101563935B (zh) * | 2006-12-19 | 2011-12-28 | 皇家飞利浦电子股份有限公司 | 将二维视频转换为三维视频的方法和系统 |
JP5419718B2 (ja) * | 2007-03-19 | 2014-02-19 | コーニンクレッカ フィリップス エヌ ヴェ | 磁気共鳴装置及び方法 |
EP1985312A1 (en) * | 2007-04-25 | 2008-10-29 | Koninklijke Philips Electronics N.V. | T1 reduction in 19F magnetic resonance imaging (MRI) |
KR101005561B1 (ko) * | 2008-06-21 | 2011-01-05 | 한국생명공학연구원 | 광학특성 나노입자 및 퍼플루오로카본으로 구성된 나노에멀젼을 이용한 다중모드 조영 방법 |
CN102395548A (zh) * | 2009-04-15 | 2012-03-28 | 奥斯金生医公司 | 全氟化碳类乳液 |
-
2010
- 2010-07-21 US US13/387,748 patent/US20120128589A1/en not_active Abandoned
- 2010-07-21 CN CN201080041769.8A patent/CN102497888B/zh not_active Expired - Fee Related
- 2010-07-21 JP JP2012522296A patent/JP5840609B2/ja not_active Expired - Fee Related
- 2010-07-21 WO PCT/IB2010/053321 patent/WO2011013038A2/en active Application Filing
- 2010-07-21 EP EP10740399.0A patent/EP2459235B1/en not_active Not-in-force
-
2015
- 2015-11-12 JP JP2015221770A patent/JP2016029098A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016029098A (ja) | 2016-03-03 |
EP2459235B1 (en) | 2014-04-23 |
JP2013500959A (ja) | 2013-01-10 |
WO2011013038A3 (en) | 2011-05-05 |
CN102497888A (zh) | 2012-06-13 |
WO2011013038A2 (en) | 2011-02-03 |
EP2459235A2 (en) | 2012-06-06 |
US20120128589A1 (en) | 2012-05-24 |
CN102497888B (zh) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bort et al. | EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles | |
Arms et al. | Advantages and limitations of current techniques for analyzing the biodistribution of nanoparticles | |
Park et al. | Towards clinically translatable in vivo nanodiagnostics | |
Ehlerding et al. | Big potential from small agents: nanoparticles for imaging-based companion diagnostics | |
Li et al. | Multimodality imaging in nanomedicine and nanotheranostics | |
Mi et al. | A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy | |
Kunjachan et al. | Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects | |
Hahn et al. | Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives | |
Iyad et al. | Gadolinium contrast agents-challenges and opportunities of a multidisciplinary approach: Literature review | |
Serkova et al. | Preclinical applications of multi-platform imaging in animal models of cancer | |
Lanza et al. | 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles | |
Mirabello et al. | Metallic nanoparticles as synthetic building blocks for cancer diagnostics: from materials design to molecular imaging applications | |
Hsu et al. | Nanomaterial-based contrast agents | |
Misri et al. | Nanoprobes for hybrid SPECT/MR molecular imaging | |
Pallares et al. | Nanoparticle diagnostics and theranostics in the clinic | |
Wu et al. | Nanoparticle‐based imaging of inflammatory bowel disease | |
Gonawala et al. | Application of dendrimer-based nanoparticles in glioma imaging | |
Opacic et al. | Status and trends in the development of clinical diagnostic agents | |
Tuguntaev et al. | Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations | |
WO2009129482A1 (en) | Methods and compositions for molecular imaging | |
Calle et al. | Advanced contrast agents for multimodal biomedical imaging based on nanotechnology | |
Wang et al. | Exponential growth of publications on carbon nanodots by Chinese authors | |
JP5840609B2 (ja) | イメージングに用いるパーフルオロ化合物 | |
JP2020019763A (ja) | マルチモーダルpet/mri造影剤およびその合成方法 | |
JP2013500959A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130719 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140729 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20141028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5840609 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |